Value of information analysis for a new technology: Computerassisted total knee replacement

Hengjin Dong

Heidelberg University

Doug Coyle

University of Ottawa

Martin Buxton

Brunel University

Objectives: The aim of this study was to demonstrate how value of information analysis can measure the upper limit on returns to future research and identify the research priorities for computer-assisted total knee replacement (CAS-TKR).

Methods: Using a previous economic analysis of CAS-TKR compared with conventional TKR, the population expected value of perfect information (EVPI) was calculated using Monte Carlo simulation to provide an estimate of the upper limit on returns to future research. The population expected value of partial perfect information (EVPPI) for both individual parameters and groups of parameters was estimated to inform specific future research priorities.

Results: The UK individual EVPI would be £21.4 if the willingness to pay for one QALY (quality-adjusted life-year) were £30,000. The population EVPPI would be £8.3 million, assuming a 10-year time horizon for CAS-TKR. In this instance, the expected value of information is positively related to willingness to pay for one QALY for the range of £0 to £50,000. Although each individual parameter had an EVPPI of £0, groups of utility parameters had positive EVPPI. Population EVPPI was £5.6 million for utility parameters, £20,000 for transition probabilities relating to CAS-TKR, and £5,000 for transition probabilities relating TKR.

Conclusions: The study provides evidence on which parameters further information may be of most value. Focusing research on the utility values associated with health states relating to TKR would be of greatest value.

Keywords: Total knee replacement, Computer-assisted surgery, Value of information analysis

Cost-effectiveness analysis (CEA) compares the costs and health outcomes of interventions to determine which intervention or policy is optimal given society's willingness to

The authors acknowledge support of this work through the *MATCH* Programme (*EPSRC* Grant GR/S29874/01), although the views expressed are entirely their own. Financial support to *MATCH* comes from several public and private sources including DePuy International Ltd. The authors have no personal conflict of interest with regard to this project. pay (WTP) for health outcomes. It is one of several criteria that should be used in decision making to inform the decision to adopt a technology, or not, given current knowledge. However, in the case of new technologies analyzed at an early stage in their cycle, considerable uncertainty about parameter values is likely when estimating cost-effectiveness. Decision makers need both to consider the uncertainties while making an immediate decision about adoption and to decide whether further research should be undertaken to reduce uncertainty in that decision. The expected value of information (EVI) theory in medical decision making is one such analytical technique that can identity the priorities for further research. The expected cost of making decisions under uncertainty can be referred to as the expected value of perfect information (EVPI) as it is the maximum a decision maker should be willing to pay to remove uncertainty concerning a decision (1). It is determined jointly by the probability that a decision based on existing information will be wrong and the consequences of the wrong decision. Within decision analysis, all parameters contribute to decision uncertainty. Estimating the expected value of partial perfect information (EVPPI) provides information on which parameters contribute most to this uncertainty and can provide the basis from which to determine future research priorities.

Total knee replacement (TKR) itself is a well-proven procedure. The demand for TKR is increasing mainly because of longer life expectancies and rising public expectations for quality of life and mobility in later years. TKR usually produces excellent results, although serious complications occur in around 5 percent of cases because of loosening, instability, dislocation, infection, or fracture (13). In 20–60 percent of patients, less serious complications such as anterior knee pain or limited movement are reported at approximately 3 years after operation (9–11). The surgeon's experience in patient selection, soft-tissue balancing, the alignment of the leg, the restoration of the joint line, and also the prosthetic design are all possible factors influencing the success of TKR (7).

Computer-assisted surgery (CAS) systems have been developed to improve limb and component alignment in TKR. However, as yet there is limited evidence of its contribution to the cost-effectiveness of TKR, although some studies of effectiveness have been undertaken (2–4;16). A Markov model had previously been used to make a preliminary assessment of the cost-effectiveness of computer-assisted TKR with that of conventional TKR (8). That study found, based on evidence from short-term radiographic studies demonstrating an improvement in the accuracy and precision of component and mechanical axis alignment with CAS and studies linking implant survival outcomes to these same alignments, that compared with conventional TKR, computer-assisted TKR is highly likely to be cost-saving and to offer a small quality-adjusted life-year (QALY) advantage.

However, there are multiple sources of uncertainty (e.g., utility values, costs, transition probabilities, and the effect of CAS) in the model. This finding is accentuated by the lack of long-term evidence from randomized clinical trials, which would provide a more definitive assessment of costeffectiveness. Thus, in this study, value of information analysis is applied to measure the upper limit on returns to future research and to identify parameters for which future research may be warranted.

METHODOLOGY

Markov Model and Monte Carlo Simulation

In our previous study (8), we designed a nine-state Markov model (Figure 1). A 10-year cohort simulation with a starting number of 1,000 TKRs was carried out. We selected a time horizon of 10 years given the average age of patients at operation was 70. Effectiveness was expressed by QALYs. Both costs and QALYs were discounted at 3.5 percent in line with 2003 Treasury guidelines (12). The differences between CAS and the conventional technique were expressed by the incremental cost-effectiveness ratio (ICER).

The model was made probabilistic using Monte Carlo simulation (MCS). We refined the model not only by keeping the hierarchical relationship between the utilities of states "Normal health after primary TKR," "TKR with serious complications," and "TKR with minor complications" in our previous study (8), but also by retaining the hierarchical relationship between the costs of states "Complex revision," "Simple revision," and "TKR operation for knee problem" in the simulation. We ran 10,000 120-cycle (a cycle length is 1 month) cohort simulations trials, randomly sampling from the distributions of transition probabilities, costs, and utilities. The assumed parameter distribution was showed in Table 1. In each of the 10,000 simulated trials, we calculated the net benefits of both CAS and conventional techniques at the level of £30,000 per QALY, the upper value suggested by the National Institute for Health and Clinical Excellence (15).

EVPI

EVPI is the difference between "the average of the maximized net-benefits" and "the maximum of the averages." It refers to the expected value of information per individual presenting at the decision point. This value can be calculated as follows: (i) Conduct an MCS by sampling from the probability density functions for all parameters. (ii) Calculate the mean net benefits for each treatment option, and identify the optimal option as that with the maximum net benefits. (iii) For each replication within the MCS, calculate the difference between the net benefits of the optimal treatment and the maximum net benefits across all treatments. (iv) EVPI is the expected value from step iii.

Population EVPI

Population EVPI reflects the effective EVI that is relevant to a decision about further research. Population EVPI equals individual EVPI multiplied by the discounted effective population over a time horizon of the technology. The effective "population" of TKR operations per year was assumed as 44,898 in England and Wales (14). The time horizon over which the information on CAS-TKR would be relevant to decision makers was assumed as 5, 10, 15, and 20 years, so that we could see the change of population EVPI in



Figure 1. Markov state transition model for total knee replacement (TKR).

quantity as the increase of the time horizon of a technology. The discount rate is 3.5 percent.

EVPPI and Population EVPPI

The EVPPI is the difference between the expected value of a decision made with perfect information about a particular parameter and the current optimal decision. Several methods for estimating individual EVPPI have been suggested (5;6). For this analysis, we adopted a two-stage MCS approach, which is calculated as follows: (i) Single values are randomly selected from the probability density functions of the parameters for which we wish to estimate EVPPI. (ii) The parameters are fixed at the values selected in step i, and the net benefit for all treatment options is estimated by conducting MCS by sampling from the probability density functions of all other parameters. (iii) For each simulation conducted in step ii, the net benefit of the optimum therapy from the base analysis is subtracted from the maximum net benefit over all therapeutic options. (iv) Steps i-iii are repeated numerous times with different sets of values for the parameters of interest. (v) EVPPI is then the expectation of values obtained from repeating step iii.

Population EVPPI equals the individual EVPPI multiplied by the discounted effective population over a time horizon of the technology. Population EVPPI is a function of the chosen time horizon of a technology. However, the rank order of EVPPIs will be the same regardless of the different time horizon.

RESULTS

Markov Model and Distributions of Parameters

Figure 1 shows the nine-state Markov model and the transition relationship between the health states. Table 1 shows the distributions of the parameters in the Markov model. Uncertainties around the cost-related parameters were characterized by Gamma distribution function, making the distributions skewed with a lower bound of 0. Uncertainties around the utility values were characterized by a Beta distribution function, which has bounds of 0 and 1. Uncertainties around the transition probabilities were characterized by the Dirichlet distribution function—the multinomial equivalent to the Beta distribution (8).

Individual and Population EVPI

Figure 2 shows the EVPI for the UK population with TKR for different assumed time horizons of the technology, from 5 years to 20 years. In this instance, the population EVPI increase with the amount of WTP for one QALY is shown. If the WTP for one QALY were £30,000, the population EVPI assuming a 10-year time horizon for CAS-TKR would be £8.3 million, while the individual EVPI would be £21.4.

EVPPI

The overall EVPI for the model is a useful upper limit on returns to future research. However, of crucial importance

Table 1. Distributions of Assumed Farameters	Table 1.	Distributions	of Assumed	Parameters
--	----------	---------------	------------	------------

Parameters	Mean	Range
Cost related (£)		
TKR operation for knee problem	5,197	121-10,090
Simple revision	6,234	1,337-11,032
Complex revision	7,326	4,161-11,741
Other treatments	2,844	1,467-5,625
Utility related		
TKR operation for knee problem	.72	.00026-1
Normal health after primary TKR	.78	.00026-1
TKR with minor complications	.66	.00000-1
TKR with serious complications	.35	.0000079542
Simple revision	.66	.00076-1
Complex revision	.51	.0000099997
Other treatments	.72	.00005-1
Normal health after TKR revision	.68	.00004-1
Transition related		
TKR operation for knee problem \rightarrow Normal health after primary TKR	.94220	.9160696639
TKR operation for knee problem \rightarrow TKR with minor complications	.04285	.0233807686
TKR operation for knee problem \rightarrow TKR with serious complications	.01495	.0057603355
Serious complication \rightarrow Minor complication	.01385	.0042803200
Serious complication \rightarrow Complex revision	.02469	.0114104978
Serious complication \rightarrow Simple revision	.00523	.0007301763
Serious complication \rightarrow Other treatments	.95236	.9302797291
Minor complication \rightarrow Serious complication	.00921	.0032702704
Minor complication \rightarrow Normal health after primary TKR	.94236	.91959–.96569
Minor complication \rightarrow Simple revision	.00250	.0001101224
Minor complication \rightarrow Other treatments	.01701	.0078004165
Remain in the minor complication state	.02505	.0121404941
Normal health after primary TKR \rightarrow Minor complication	.01385	.0037203206
Normal health after primary TKR \rightarrow Serious complication	.00921	.0026702568
Remain in the normal health after primary TKR state	.97307	.9539798925
Complex revision \rightarrow Serious complication	.02545	.0128905332
Complex revision \rightarrow Normal health after TKR revision	.96963	.9506398668
Simple revision \rightarrow Serious complication	.01590	.0069603382
Simple revision \rightarrow Minor complication	.00816	.0023502361
Simple revision \rightarrow Other treatments	.01701	.0062103753
Simple revision \rightarrow Normal health after TKR revision	.95400	.9335397556
Other treatments \rightarrow Serious complication	.00921	.0023202643
Other treatments \rightarrow Minor complication	.01385	.0063303213
Other treatments \rightarrow Simple revision	.00250	.0000701361
Other treatments \rightarrow Normal health after primary TKR	.97057	.9407098605
Normal health after TKR revision \rightarrow Complex revision	.02003	.0092503904
Normal health after TKR revision \rightarrow Simple revision	.01038	.0030802717
Remain in the normal health after TKR revision state	.96468	.9450298283
Death probability related to TKR for patients after primary TKR	.00046	.0000000709
Death probability related to revision for patients after TKR revision	.00151	.0000200959
Death related to all reasons	.00341	.0002101598
CAS related		
Effect of CAS	.33910	.0826195753
Extra cost of CAS	235	110-498

Note. Gamma distribution is used for cost-related parameters. Beta distribution is used for utility-related parameters. Lognormal distribution is used for "effect of CAS," and the Dirichlet distribution is used for transition-related parameters. TKR, total knee replacement; CAS, computer-assisted surgery.

is which particular parameters (or groups of related parameters) are most important in terms of representing the greatest value of information. In the EVPPI analyses (10-year time horizon of the technology), all individual parameters had an EVPPI of 0. However, three groups of parameters had positive EVPPIs (Table 2). Population EVPPI was £5.6 million for utility parameters, £20,000 for transition probabilities relating to CAS-TKR, and £5,000 for transition probabilities related to conventional TKR.



Figure 2. EVPI for UK population with TKR. EVPI, expected value of perfect information; TKR, total knee replacement; QALY, quality-adjusted life-year.

Table 2. EVPPI for Parameter Groups

Parameter group	EVPPI (£)	
Conventional TKR cost-related parameters		
CAS-TKR cost-related parameters	0	
Utility-related parameters	14.4859	
Conventional TKR transition-related parameters	.0128	
CAS-TKR transition-related parameters	.0447	
Both effect of CAS and extra cost of CAS	0	

Note. EVPPI was calculated based on a WTP of £30,000/quality-adjusted life-year. All individual parameters had an EVPPI of 0.

EVPPI, expected value of partial perfect information; TKR, total knee replacement; CAS, computer-assisted surgery; WTP, willingness to pay.

DISCUSSION

In our earlier study (8), based on short-term evidence from the studies that have compared the clinical effectiveness of CAS with that of conventional TKR in terms of correct alignment of components, we found that compared with conventional TKR, computer-assisted TKR is a cost-saving technology in the long-term and may offer small additional QALYs.

Our analysis here of the value of additional information related to specific parameters or parameter groups confirms the results of parameter importance analysis from our early study (8). Using the analysis of covariance approach to explore the proportion of the total model sum of squares that is explained by each individual input parameter, it was found that utility-related parameters and transition probabilities were the most important.

However, population EVPI and EVPPI are more informative measures of parameter importance as they measure the maximum possible payoff to additional research. The population partial EVPI can help to focus research priorities as it allows identification of the parameters contributing most to decision uncertainty (5). In our earlier study (8), it was found that, at £30,000 per QALY, there was a 92 percent probability that CAS was the more cost-effective technology. Given this high degree of certainty, it is not surprising that individual EVPI is not high, although given the high use of the technology population EVPI is of more interest.

The key assumption in the earlier study was that CAS surgery, due to improving alignment of components, could reduce complication rate and revision rate. This assumption is associated with a high degree of uncertainty because of the lack of direct longer-term evidence in support. However, despite this degree of uncertainty, the partial value of perfect information showed that transition-related parameters have only limited information value, and to be justified, future research related to these parameters would have to have value for decision making relating to a large number of patients outside the UK setting.

In the value of information analysis, the annual size for the relevant patient population and the time horizon over which the evidence is relevant (and, hence, the size of the total patient population who might benefit from a reduction in uncertainty) are critical parameters and can only be a matter of judgment. Moreover, these two parameters may well differ for different items of information. For example, reducing the uncertainty around the effectiveness of CAS will only be relevant as long as the specific technology does not change or develop—which is likely to be a relatively short time period. However, during this short period, wellconducted studies of relative effectiveness would probably have relevance to patients in a range of countries where the

Dong et al.

technology might be adopted (our analysis only considers patients in England and Wales).

On the other hand, better estimates of patient utilities in different health states might have longer-term relevance (for the evaluation of future developments in TKR surgery) in the United Kingdom but might not necessarily be seen as generalizable to patients from all other countries interested in the technology. UK cost data are likely to be of interest only in the United Kingdom and to be relatively rapidly outdated. Thus, comparison of (UK) population EVPPI for different parameters judged under a single time horizon may be misleading in terms both of the value beyond the UK population and for different time horizons.

Furthermore, special attention should be paid to generalizing the results of the current study to other countries. We did the analysis from the UK National Health Service point of view in terms of the relevant costs. Other countries will have different cost structures for these procedures, which would influence the mean value and variance of the cost in each health state. Thus, our results can only provide information for UK decision makers and may not be applicable in other countries. It is encouraged that other countries repeat the analysis applying their own cost and size of relevant patient patients.

In addition, population EVPI and EVPPI are the upper limit for additional research in one country. If analysis were repeated in other countries, the EVPI for parameters that are common across countries would be greater, providing greater rationale for a coordinated program of future research.

CONCLUSION

Based on the value of information analysis, from a UK perspective, it is likely to be worthwhile to have additional research related to patient utilities at different health states. Further research related to transition probabilities may be of value, but only from a more global perspective.

CONTACT INFORMATION

Hengjin Dong, MD, PhD (dong@uni-heidelberg.de), Junior group of International Health Economics and Technology Assessment, Department of Tropical Hygiene and Public Health, Heidelberg University, INF 324, D-69120, Heidelberg, Germany

Doug Coyle, PhD (dcoyle@uottawa.ca), Associate Professor, Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 4H5, Canada **Martin Buxton**, BA (Soc Sci), (martin.buxton@brunel. ac.uk), Professor of Health Economics, Health Economics Research Group, Brunel University, Cleveland Road, Uxbridge, Middlesex UB8 3PH, UK

REFERENCES

- Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. *Med Decis Making*. 2004;24:207-227.
- Bathis H, Perlick L, Tingart M, et al. Alignment in total knee arthroplasty. A comparison of computer-assisted surgery with the conventional technique. *J Bone Joint Surg Br.* 2004;86:682-687.
- 3. Chauhan SK, Clark GW, Lloyd S, et al. Computer-assisted total knee replacement. A controlled cadaver study using a multiparameter quantitative CT assessment of alignment (the Perth CT Protocol). *J Bone Joint Surg Br.* 2004;86:818-823.
- Chauhan SK, Scott RG, Breidahl W, Beaver RJ. Computerassisted knee arthroplasty versus a conventional jig-based technique. A randomised, prospective trial. *J Bone Joint Surg Br*. 2004;86:372-377.
- Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. *Int J Technol Assess Health Care*. 2001;17:38-55.
- Coyle D, Buxton MJ, O'Brien BJ. Measures of importance for economic analysis based on decision modeling. J Clin Epidemiol. 2003;56:989-997.
- 7. Delp SL, Stulberg SD, Davies B, Picard F, Leitner F. Computer assisted knee replacement. *Clin Orthop.* 1998:49-56.
- Dong H, Buxton M. Early assessment of the likely costeffectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. *Int J Technol Assess Health Care*. 2006;22:191-202.
- 9. Figgie HE III, Goldberg VM, Heiple KG, Moller HS III, Gordon NH. The influence of tibial-patellofemoral location on function of the knee in patients with the posterior stabilized condylar knee prosthesis. *J Bone Joint Surg Am.* 1986;68:1035-1340.
- 10. Gaweda K, Jablonski M. Function of patellofemoral joints after total knee replacement with polyethylene patellar articular surface in osteoarthritis and rheumatoid arthritis. *J Orthopaed Traumatol.* 2000;2:79-82.
- 11. Hassaballa MA, Porteous AJ, Newman JH. Observed kneeling ability after total, unicompartmental and patellofemoral knee arthroplasty: Perception versus reality. *Knee Surg Sports Traumatol Arthrosc.* 2004;12:136-139.
- Her Majesty's Treasury. Appraisal and evaluation in central government. 2003. Available at: URL://greenbook.treasury. gov.uk.
- Kane RL, Saleh KJ, Wilt TJ, et al. Total knee replacement. Evidence Report/Technology Assessment No. 86 (prepared by Minnesota Evidence-based Practice Center, Minneapolis, Minnesota). AHRQ Publication No. 04-E006-1. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
- National Joint Registry for England and Wales. 2005. 2nd annual report. Available at: http://www.njrcentre.org.uk/ documents/reports/NJR2_part_2.pdf; Accessed: March 21, 2006.
- 15. NHS National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NHS National Institute for Clinical Excellence; 2004.
- Sparmann M, Wolke B, Czupalla H, Banzer D, Zink A. Positioning of total knee arthroplasty with and without navigation support. A prospective, randomised study. *J Bone Joint Surg Br*. 2003;85:830-835.

342 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 23:3, 2007